

## Navigation Aids

List of Requirements	440
Acronyms and Abbreviations	448
Glossary	452
Index	458

# List of Requirements

The list below outlines compliance with key annual performance reporting information, as required in section 17AJ(d) of the *Public Governance, Performance and Accountability Rule 2014*.

PGPA Rule Reference	Part of Report	Description	Requirement	Location
<b>17AD(g) Letter of Transmittal</b>				
17AI		A copy of the letter of transmittal signed and dated by the accountable authority on date final text approved, with statement that the report has been prepared in accordance with section 46 of the PGAA Act and any enabling legislation that specifies additional requirements in relation to the annual report.	Mandatory	Page 1
<b>17AD(h) Aids to Access</b>				
17AJ(a)		Table of contents.	Mandatory	Page 2-3
17AJ(b)		Alphabetical index.	Mandatory	Page 458
17AJ(c)		Glossary of abbreviations and acronyms.	Mandatory	Page 448
17AJ(d)		List of requirements.	Mandatory	Page 440
17AJ(e)		Details of contact officer.	Mandatory	Page ii
17AJ(f)		Entity's website address.	Mandatory	Page ii
17AJ(g)		Electronic address of report.	Mandatory	Page ii
<b>17AD(a) Review by Accountable Authority</b>				
17AD(a)		A review by the accountable authority of the entity.	Mandatory	Page 4
<b>17AD(b) Overview of the Entity</b>				
17AE(1)(a)(i)		A description of the role and functions of the entity.	Mandatory	Part 1
17AE(1)(a)(ii)		A description of the organisational structure of the entity.	Mandatory	Page 29

PGPA Rule Reference	Part of Report	Description	Requirement	Location
17AE(1)(a)(iii)		A description of the outcomes and programs administered by the entity.	Mandatory	Page 34
17AE(1)(a)(iv)		A description of the purposes of the entity as included in corporate plan.	Mandatory	Page 26
17AE(1)(b)		An outline of the structure of the portfolio of the entity.	Portfolio departments - mandatory	Page 28
17AE(2)		Where the outcomes and programs administered by the entity differ from any Portfolio Budget Statements, Portfolio Additional Estimates Statements or other portfolio estimates statements that was prepared for the entity for the period, include details of variation and reasons for change.	If applicable, Mandatory	Page 28
<b>17AD(c)</b>	<b>Report on the Performance of the Entity</b>			
	<i>Annual Performance Statements</i>			<b>Part 2</b>
17AD(c)(i); 16F		Annual Performance Statement in accordance with paragraph 39(1)(b) of the Act and section 16F of the Rule.	Mandatory	Part 2
<b>17AD(c)(ii)</b>	<b>Report on Financial Performance</b>			<b>Part 1</b>
17AF(1)(a)		A discussion and analysis of the entity's financial performance.	Mandatory	Pages 16-17 & Part 4
17AF(1)(b)		A table summarising the total resources and total payments of the entity.	Mandatory	Page 222
17AF(2)		If there may be significant changes in the financial results during or after the previous or current reporting period, information on those changes, including: the cause of any operating loss of the entity; how the entity has responded to the loss and the actions that have been taken in relation to the loss; and any matter or circumstances that it can reasonably be anticipated will have a significant impact on the entity's future operation or financial results.	If applicable, Mandatory.	Page 17 & Part 4

PGPA Rule Reference	Part of Report	Description	Requirement	Location
<b>17AD(d)</b>	<b>Management and Accountability</b>			
	<i>Corporate Governance</i>			<b>Part 3.1</b>
17AG(2)(a)		Information on compliance with section 10 (fraud systems).	Mandatory	Part 3.1
17AG(2)(b)(i)		A certification by accountable authority that fraud risk assessments and fraud control plans have been prepared.	Mandatory	Page 233
17AG(2)(b)(ii)		A certification by accountable authority that appropriate mechanisms for preventing, detecting incidents of, investigating or otherwise dealing with, and recording or reporting fraud that meet the specific needs of the entity are in place.	Mandatory	Page 233
17AG(2)(b)(iii)		A certification by accountable authority that all reasonable measures have been taken to deal appropriately with fraud relating to the entity.	Mandatory	Page 233
17AG(2)(c)		An outline of structures and processes in place for the entity to implement principles and objectives of corporate governance.	Mandatory	Part 3.1
17AG(2)(d) – (e)		A statement of significant issues reported to Minister under paragraph 19(1)(e) of the Act that relates to non-compliance with Finance law and action taken to remedy non-compliance.	If applicable, Mandatory	Not applicable
	<i>External Scrutiny</i>			<b>Part 3.2</b>
17AG(3)		Information on the most significant developments in external scrutiny and the entity's response to the scrutiny.	Mandatory	Part 3.2
17AG(3)(a)		Information on judicial decisions and decisions of administrative tribunals and by the Australian Information Commissioner that may have a significant effect on the operations of the entity.	If applicable, Mandatory	Part 3.2
17AG(3)(b)		Information on any reports on operations of the entity by the Auditor-General (other than report under section 43 of the Act), a Parliamentary Committee, or the Commonwealth Ombudsman.	If applicable, Mandatory	Part 3.2
17AG(3)(c)		Information on any capability reviews on the entity that were released during the period.	If applicable, Mandatory	Not applicable

PGPA Rule Reference	Part of Report	Description	Requirement	Location
<b>Management of Human Resources</b>				<b>Part 3.4 &amp; Part 3.5</b>
17AG(4)(a)		An assessment of the entity's effectiveness in managing and developing employees to achieve entity objectives.	Mandatory	Part 3.4
17AG(4)(b)		<p>Statistics on the entity's APS employees on an ongoing and non-ongoing basis; including the following:</p> <ul style="list-style-type: none"> <li>• Statistics on staffing classification level;</li> <li>• Statistics on full-time employees;</li> <li>• Statistics on part-time employees;</li> <li>• Statistics on gender;</li> <li>• Statistics on staff location;</li> <li>• Statistics on employees who identify as Indigenous.</li> </ul>	Mandatory	Part 3.5
17AG(4)(c)		Information on any enterprise agreements, individual flexibility arrangements, Australian workplace agreements, common law contracts and determinations under subsection 24(1) of the <i>Public Service Act 1999</i> .	Mandatory	Part 3.4
17AG(4)(c)(i)		Information on the number of SES and non-SES employees covered by agreements etc. identified in paragraph 17AG(4)(c).	Mandatory	Part 3.4 & Part 3.5
17AG(4)(c)(ii)		The salary ranges available for APS employees by classification level.	Mandatory	Part 3.5
17AG(4)(c)(iii)		A description of non-salary benefits provided to employees.	Mandatory	Part 3.5
17AG(4)(d)(i)		Information on the number of employees at each classification level who received performance pay.	If applicable, Mandatory	Part 3.5
17AG(4)(d)(ii)		Information on aggregate amounts of performance pay at each classification level.	If applicable, Mandatory	Part 3.5
17AG(4)(d)(iii)		Information on the average amount of performance payment, and range of such payments, at each classification level.	If applicable, Mandatory	Part 3.5

PGPA Rule Reference	Part of Report	Description	Requirement	Location
17AG(4)(d)(iv)		Information on aggregate amount of performance payments.	If applicable, Mandatory	Part 3.5
<b>Assets Management</b>				<b>Part 3.3</b>
17AG(5)		An assessment of effectiveness of assets management where asset management is a significant part of the entity's activities.	If applicable, mandatory	Part 3.3
<b>Purchasing</b>				<b>Part 3.3</b>
17AG(6)		An assessment of entity performance against the <i>Commonwealth Procurement Rules</i> .	Mandatory	Part 3.3
<b>Consultants</b>				<b>Part 3.3</b>
17AG(7)(a)		A summary statement detailing the number of new contracts engaging consultants entered into during the period; the total actual expenditure on all new consultancy contracts entered into during the period (inclusive of GST); the number of ongoing consultancy contracts that were entered into during a previous reporting period; and the total actual expenditure in the reporting year on the ongoing consultancy contracts (inclusive of GST).	Mandatory	Part 3.3
17AG(7)(b)		A statement that <i>"During 2015-16, 421 new consultancy contracts were entered into involving total actual expenditure of \$22.6 million. In addition, 327 ongoing consultancy contracts were active during 2015-16 involving total actual expenditure of \$23.8 million."</i>	Mandatory	Part 3.3
17AG(7)(c)		A summary of the policies and procedures for selecting and engaging consultants and the main categories of purposes for which consultants were selected and engaged.	Mandatory	Part 3.3
17AG(7)(d)		A statement that <i>"Annual reports contain information about actual expenditure on contracts for consultancies. Information on the value of contracts and consultancies is available on the AusTender website."</i>	Mandatory	Part 3.3

PGPA Rule Reference	Part of Report	Description	Requirement	Location
<b>Australian National Audit Office Access Clauses</b>				<b>Part 3.3</b>
17AG(8)		If an entity entered into a contract with a value of more than \$100,000 (inclusive of GST) and the contract did not provide the Auditor-General with access to the contractor's premises, the report must include the name of the contractor, purpose and value of the contract, and the reason why a clause allowing access was not included in the contract.	If applicable, Mandatory	Not applicable
<b>Exempt Contracts</b>				<b>Part 3.3</b>
17AG(9)		If an entity entered into a contract or there is a standing offer with a value greater than \$10 000 (inclusive of GST) which has been exempted from being published in AusTender because it would disclose exempt matters under the FOI Act, the annual report must include a statement that the contract or standing offer has been exempted, and the value of the contract or standing offer, to the extent that doing so does not disclose the exempt matters.	If applicable, Mandatory	Part 3.3
<b>Small Business</b>				<b>Part 3.3</b>
17AG(10)(a)		A statement that <i>"the Department of Health supports small business participation in the Commonwealth Government procurement market. Small and Medium Enterprises (SME) and Small Enterprise participation statistics are available on the Department of Finance's website."</i>	Mandatory	Part 3.3
17AG(10)(b)		An outline of the ways in which the procurement practices of the entity support small and medium enterprises.	Mandatory	Part 3.3
17AG(10)(c)		If the entity is considered by the Department administered by the Finance Minister as material in nature — a statement that <i>"the Department recognises the importance of ensuring that small businesses are paid on time. The results of the Survey of Australian Government Payments to Small Business are available on the Treasury's website: <a href="http://www.treasury.gov.au">www.treasury.gov.au</a>"</i>	If applicable, Mandatory	Part 3.3

PGPA Rule Reference	Part of Report	Description	Requirement	Location
<i>Financial Statements</i>				<b>Part 4</b>
17AD(e)		Inclusion of the annual financial statements in accordance with subsection 43(4) of the Act.	Mandatory	Part 4
<b>17AD(f)</b>	<b>Other Mandatory Information</b>			
17AH(1)(a)(i)		<p>If the entity conducted advertising campaigns, a statement that “<i>During 2015-16, the Department conducted the following advertising campaigns:</i></p> <ul style="list-style-type: none"> <li>• <i>BreastScreen Australia system campaign</i></li> <li>• <i>Girls Make Your Move campaign</i></li> <li>• <i>Health Star Rating system campaign</i></li> <li>• <i>National Bowel Cancer Screening Program campaign</i></li> <li>• <i>National Drugs campaign</i></li> <li>• <i>National Tobacco campaign</i></li> </ul> <p><i>Further information on those advertising campaigns is available at <a href="http://www.health.gov.au">www.health.gov.au</a>, and in the reports on Australian Government advertising prepared by the Department of Finance and published at <a href="http://www.finance.gov.au/advertising/">www.finance.gov.au/advertising/</a>”</i></p>	If applicable, Mandatory	Part 3.9
17AH(1)(a)(ii)		If the entity did not conduct advertising campaigns, a statement to that effect.	If applicable, Mandatory	Not applicable
17AH(1)(b)		A statement that “ <i>Information on grants awarded by the Department during the period 1 July 2015 to 30 June 2016 is available at: <a href="http://www.health.gov.au/internet/main/publishing.nsf/Content/pfps-grantsreporting">www.health.gov.au/internet/main/publishing.nsf/Content/pfps-grantsreporting</a>”</i>	If applicable, Mandatory	Part 3.3
17AH(1)(c)		Outline of mechanisms of disability reporting, including reference to website for further information.	Mandatory	Part 3.7



PGPA Rule Reference	Part of Report	Description	Requirement	Location
17AH(1)(d)		Website reference to where the entity's Information Publication Scheme statement pursuant to Part II of FOI Act can be found.	Mandatory	Page 240
17AH(1)(e)		Correction of material errors in previous annual report.	If applicable, Mandatory	Not applicable
17AH(2)		Information required by other legislation.	Mandatory	Part 3.2 & Appendices

# Acronyms and Abbreviations

## A

<b>ABS</b>	Australian Bureau of Statistics
<b>ACAP</b>	Aged Care Assessment Program
<b>ACAT</b>	Aged Care Assessment Team
<b>AGPT</b>	Australian General Practice Training Ltd.
<b>AHMAC</b>	Australian Health Ministers' Advisory Council
<b>AIDS</b>	Acquired Immune Deficiency Syndrome
<b>AIHW</b>	Australian Institute of Health and Welfare
<b>AIR</b>	Australian Immunisation Register
<b>AMR</b>	Antimicrobial Resistance
<b>ANAO</b>	Australian National Audit Office
<b>ANFPP</b>	Australian Nurse Family Partnership Program
<b>ANPHA</b>	Australian National Preventive Health Agency
<b>APEC</b>	Asia-Pacific Economic Cooperation
<b>APRA</b>	Australian Prudential Regulation Authority
<b>APS</b>	Australian Public Service
<b>APSC</b>	Australian Public Service Commission
<b>APVMA</b>	Australian Pesticides and Veterinary Medicines Authority
<b>ASADA</b>	Australian Sports Anti-Doping Authority
<b>AURA</b>	Antimicrobial Use and Resistance in Australia

## B

<b>BBV</b>	Blood Borne Virus(es)
<b>BTF</b>	Biomedical Translation Fund

**C**

<b>CALD</b>	Culturally and Linguistically Diverse
<b>COAG</b>	Council of Australian Governments
<b>CTF</b>	Clinical Training Funding
<b>CSO</b>	Community Services Obligations

**D**

<b>DBMAS</b>	Dementia Behaviour Management Advisory Service
<b>DHS</b>	Department of Human Services
<b>DIAS</b>	Diagnostic Imaging Accreditation Scheme
<b>DSS</b>	Department of Social Services

**E**

<b>EL</b>	Executive Level
<b>ESD</b>	Ecologically Sustainable Development

**F**

<b>FOI</b>	Freedom of Information
<b>FTE</b>	Full-time Equivalent

**G**

<b>GM</b>	Genetically Modified
<b>GMO(s)</b>	Genetically Modified Organism(s)
<b>GP(s)</b>	General Practitioner(s)
<b>GPRIP</b>	General Practice Rural Incentives Program

**H**

<b>HIV</b>	Human Immunodeficiency Virus
<b>HPC</b>	Haemopoietic Progenitor Cell
<b>HPV</b>	Human Papillomavirus

**I**

<b>IAHP</b>	Indigenous Australians Health Programme
<b>IMAP</b>	Inventory Multi-tiered Assessment and Prioritisation
<b>INF</b>	International Netball Federation
<b>IPP</b>	Indigenous Procurement Policy
<b>ICT</b>	Information and Communication Technology
<b>IT</b>	Information Technology

**L**

- LGBTI** Lesbian, Gay, Bisexual, Transgender and Intersex  
**LSDP** Life Saving Drugs Program

**M**

- MBS** Medicare Benefits Schedule  
**MHDAPC** Mental Health Drug and Alcohol Principle Committee  
**MERS-CoV** Middle East Respiratory Syndrome Coronavirus  
**MIGA** Medical Insurance Group Australia  
**MMR** Measles, Mumps, Rubella Vaccine  
**MRFF** Medical Research Future Fund  
**MSAC** Medical Services Advisory Committee

**N**

- NABERS** National Australian Built Environment Rating Scheme  
**NAIDOC** National Aborigines and Islanders Day Observance Committee  
**NCERG** National Cancer Expert Reference Group  
**NCSP** National Cervical Screening Program  
**NDSHS** National Drug Strategy Household Survey  
**NDSS** National Diabetes Services Scheme  
**NHMRC** National Health and Medical Research Council  
**NICNAS** National Industrial Chemicals Notification and Assessment Scheme  
**NIP** National Immunisation Program  
**NIS** National Immunisation Strategy  
**NPAAC** National Pathology Accreditation Advisory Council  
**NPEV** National Partnership Agreement on Essential Vaccines  
**NPS** National Prescribing Service

**O**

- OCP(s)** Optimal Care Pathway(s)  
**OECD** Organisation for Economic Co-operation and Development  
**OGTR** Office of the Gene Technology Regulator

**P**

- PBAC** Pharmaceutical Benefits Advisory Committee  
**PBS** Pharmaceutical Benefits Scheme  
**PCC** Pathology Clinical Committee  
**PGPA** Public Governance, Performance and Accountability  
**PHN(s)** Primary Health Network(s)

<b>PIP</b>	Practice Incentives Program
<b>PSAC</b>	Pathology Services Advisory Committee
<b>R</b>	
<b>RCTS</b>	Rural Clinical Training and Support
<b>RFDS</b>	Royal Flying Doctor Service
<b>RLIF</b>	Rugby League International Federation
<b>RRTIG</b>	Rural and Regional Teaching Infrastructure Grants
<b>S</b>	
<b>SBRT</b>	Severe Behaviour Response Team
<b>SES</b>	Senior Executive Service
<b>SME</b>	Small and Medium Enterprises
<b>STI</b>	Sexually Transmissible Infection(s)
<b>SUSMP</b>	Standard for the Uniform Scheduling of Medicines and Poisons
<b>T</b>	
<b>TGA</b>	Therapeutic Goods Administration
<b>U</b>	
<b>UNESCO</b>	United Nations Educational, Scientific and Cultural Organization
<b>W</b>	
<b>WHO</b>	World Health Organization
<b>WHS</b>	Work Health and Safety

# Glossary

<b>Acute care</b>	Short-term medical treatment, usually in a hospital, for patients with an acute illness or injury, or recovering from surgery. Acute illness/injury is one that is severe in its effect or approaching crisis point, for example acute appendicitis.
<b><i>Aedes aegypti</i> and <i>Aedes albopictus</i></b>	Mosquito species that may be carriers (vectors) of dengue, yellow fever, Zika and chikungunya. In Australia, <i>Aedes aegypti</i> is only found in parts of northern, central and southwest Queensland and <i>Aedes albopictus</i> is only found in the Torres Strait.
<b>Allied health practitioners/providers</b>	For the purpose of this report, allied health practitioners/providers are those registered under the National Registration Accreditation Scheme. These professions include: Psychologists, Pharmacists, Physiotherapists, Optometrists, Chiropractors, Podiatrists, Osteopaths, Medical radiation practitioners, Dental professionals, Occupational therapists, Chinese medicine practitioners, and Aboriginal and Torres Strait Islander health practitioners.
<b>Antimicrobial resistance (AMR)</b>	The ability of a microorganism (like bacteria, viruses and parasites) to stop an antimicrobial (such as antibiotics, antivirals and antimalarials) from working against it.
<b>Blood Borne Viruses (BBV)</b>	Viruses that are transmitted through contact between infected blood and uninfected blood (e.g. hepatitis B, hepatitis C and HIV).
<b>Cervical cancer</b>	A cancer of the cervix, often caused by human papillomavirus, which is a sexually transmissible infection.
<b>Chemotherapy</b>	The treatment of disease by chemical agents, for example the use of drugs to destroy cancer cells.
<b>Chikungunya virus</b>	An alphavirus which is transmitted between people through the bite of an infected <i>Aedes albopictus</i> or <i>Aedes aegypti</i> mosquito.
<b>Chronic disease</b>	The term applied to a diverse group of diseases, such as heart disease, cancer and arthritis, that tend to be long-lasting and persistent in their symptoms or development. Although these features also apply to some communicable diseases (infections), the general term chronic diseases is usually confined to non-communicable diseases.
<b>Closing the Gap</b>	COAG Closing the Gap initiatives designed to close the life expectancy gap between Indigenous and non-Indigenous Australians.
<b>Communicable disease</b>	An infectious disease transmissible (as from person to person) by direct contact with an affected individual or the individual's discharges or by indirect means. Communicable (infectious) diseases include sexually transmitted diseases; vector-borne diseases; vaccine preventable diseases and antimicrobial resistant bacteria.
<b>Dengue virus</b>	A flavivirus, which is transmitted between people through the bite of an infected <i>Aedes aegypti</i> or <i>Aedes albopictus</i> mosquito.

<b>Diabetes</b>	Refers to a group of syndromes caused by a malfunction in the production and release of insulin by the pancreas leading to a disturbance in blood glucose levels. Type 1 diabetes is characterised by the abrupt onset of symptoms, usually during childhood, and inadequate production of insulin requiring regular injections to regulate insulin levels. Type 2 diabetes is characterised by gradual onset commonly over the age of 45 years, but increasingly occurring in younger age groups, and is usually able to be regulated through dietary control.
<b>Ebola Virus Disease</b>	Ebola virus disease, formerly known as Ebola haemorrhagic fever, is a severe, often fatal illness in humans. The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission. The average Ebola case fatality rate is around 50 per cent.
<b>eHealth</b>	Application of internet and other related technologies in the health care industry to improve the access, efficiency, effectiveness and quality of clinical and business processes utilised by health care organisations, practitioners, patients and consumers to improve the health status of patients.
<b>Elective surgery</b>	Elective care in which the procedures required by patients are listed in the surgical operations section of the Medicare Benefits Schedule, with the exclusion of specific procedures frequently done by non-surgical clinicians.
<b>Epidemic</b>	An outbreak of a disease or its occurrence at a level that is clearly higher than usual, especially if it affects a large proportion of the population.
<b>Epidermolysis Bullosa</b>	A rare inherited skin disorder which causes blistering.
<b>Financial year</b>	The 12 month period from 1 July to 30 June.
<b>Front-of-pack labelling</b>	Single, interpretive five star rating front-of-pack labelling system for use on packaged foods sold in Australia indicating nutritional content and kilojoules.
<b>General Practitioner (GP)</b>	A medical practitioner who provides primary care to patients within the community.
<b>Gene technology</b>	Gene technology involves techniques for understanding the expression of genes and taking advantage of natural genetic variation for the modification of genetic material. It does not include sexual reproduction or DNA crossover.
<b>Haemopoietic progenitor cell (HPC)</b>	Blood cells found in bone marrow, peripheral blood and umbilical cord blood that are capable of self-renewal into all blood cell types.
<b>Health care</b>	Services provided to individuals or communities to promote, maintain, monitor or restore health. Health care is not limited to medical care and includes self-care.
<b>Health outcome</b>	A change in the health of an individual or population due wholly or partly to a preventive or clinical intervention. See <b>Outcomes</b> .
<b>Hepatitis A (infectious hepatitis)</b>	An acute but benign form of viral hepatitis transmitted by ingesting food or drink that is contaminated with faecal matter.
<b>Hepatitis B (serum hepatitis)</b>	An acute (sometimes fatal) form of viral hepatitis transmitted by sexual contact, by transfusion or by ingestion of contaminated blood or other bodily fluids.

<b>Hepatitis C</b>	A blood borne viral disease that can result in serious liver disease such as cirrhosis, liver failure and liver cancer. Hepatitis C is usually transmitted by parenteral means (as injection of an illicit drug or blood transfusion or exposure to blood or blood products).
<b>Human papillomavirus (HPV)</b>	The virus that causes genital warts and which is linked in some cases to the development of more serious cervical cell abnormalities.
<b>Illicit drugs</b>	<p>The term ‘illicit drug’ can encompass a number of broad concepts including:</p> <ul style="list-style-type: none"> <li>• illegal drugs – a drug that is prohibited from manufacture, sale or possession in Australia – for example, cannabis, cocaine, heroin and ecstasy;</li> <li>• misuse or extra-medical use of pharmaceuticals – drugs that are available from a pharmacy, over-the-counter or by prescription, which may be subject to misuse – for example, opioid-based pain relief medications, opioid substitution therapies, benzodiazepines, over-the-counter codeine and steroids; and</li> <li>• other psychoactive substances – legal or illegal, potentially used in a harmful way – for example, kava, or inhalants such as petrol, paint or glue.</li> </ul>
<b>Immunisation</b>	Inducing immunity against infection by the use of an antigen to stimulate the body to produce its own antibodies. See <b>vaccination</b> .
<b>Incidence</b>	The number of new cases (of an illness or event, and so on) occurring during a given period. Compare with <b>prevalence</b> .
<b>Influenza (flu)</b>	An acute contagious viral respiratory infection marked by fevers, muscle aches, headache, cough and sore throat.
<b>Intern</b>	A doctor in their first postgraduate year and who holds provisional registration with the Medical Board of Australia.
<b>Jurisdictions</b>	In the Commonwealth of Australia, these include the Commonwealth Government, the six States, and the two Territories.
<b>Measles</b>	A highly contagious infection, usually of children, that causes flu-like symptoms, fever, a typical rash and sometimes serious secondary problems such as brain damage. Preventable by vaccine.
<b>Medical indemnity insurance</b>	A form of professional indemnity cover that provides surety to medical practitioners and their patients in the event of an adverse outcome arising from medical negligence.
<b>Medicare</b>	A national, Government-funded scheme that subsidises the cost of personal medical services for all Australians and aims to help them afford medical care. The Medicare Benefits Schedule (MBS) is the listing of the Medicare services subsidised by the Australian Government. The schedule is part of the wider Medicare Benefits Scheme (Medicare).
<b>Memorandum of Understanding</b>	A written but non-contractual agreement between two or more entities or other parties to take a certain course of action.
<b>Meningococcal disease</b>	The inflammation of meninges of the brain and the spinal cord caused by <i>meningococcal bacteria</i> which invade the body through the respiratory tract. The infection develops quickly and is often characterised by fever, vomiting, an intense headache, stiff neck and septicemia (an infection in the bloodstream).



<b>Middle East Respiratory Syndrome Coronavirus (MERS-CoV)</b>	MERS coronavirus is a disease caused by a new virus that can cause a rapid onset of severe respiratory disease in people. Most severe cases have occurred in people with underlying conditions that may make them more likely to get respiratory infections. All cases have lived in or travelled to the Middle East, or have had close contact with people who acquired the infection in the Middle East. There have been no cases in Australia.
<b>Morbidity</b>	Refers to ill health in an individual and to levels of ill health in a population or group.
<b>Mortality</b>	Death.
<b>Mumps</b>	An acute, inflammatory, contagious disease caused by a paramyxovirus and characterised by swelling of the salivary glands, especially the parotids, and sometimes of the pancreas, ovaries, or testes. This disease mainly affects children and can be prevented by vaccination.
<b>Non-communicable diseases</b>	Non-communicable diseases, also known as chronic diseases, are not passed from person to person. They are of long duration and generally slow progression. The 4 main types of non-communicable diseases are cardiovascular diseases (for example heart attacks and stroke), cancers, chronic respiratory diseases (such as chronic obstructed pulmonary disease and asthma) and diabetes.
<b>Oncology</b>	The study, knowledge and treatment of cancer and tumours.
<b>Organisation for Economic Co-operation and Development (OECD)</b>	An organisation of 34 countries including Australia, mostly developed and some emerging (such as Mexico, Chile and Turkey). The organisation's aim is to promote policies that will improve the economic and social wellbeing of people around the world.
<b>Outcomes</b>	Outcomes are the Government's intended results, benefits or consequences for the Australian community. The Government requires entities, such as the Department, to use Outcomes as a basis for budgeting, measuring performance and reporting. Annual administered funding is appropriated on an Outcomes basis. The Department's current Outcomes are listed on pages 34-35.
<b>Out-of-pocket expenses</b>	The total costs incurred by individuals for health care services over and above any refunds from Medicare and private health insurance funds.
<b>Palliative care</b>	Care provided to achieve the best possible quality of life for patients with a progressive and far-advanced disease, with little or no prospect of cure.
<b>Pathology</b>	The study and diagnosis of disease through the examination of organs, tissues, cells and bodily fluids.
<b>Pertussis (whooping cough)</b>	An extremely contagious respiratory infection caused by the bacterium <i>Bordetella pertussis</i> . The disease causes uncontrolled coughing and vomiting, which can last for several months and can be particularly dangerous for babies under the age of 12 months.
<b>Pharmaceutical Benefits Scheme (PBS)</b>	A national, Government-funded scheme that subsidises the cost of a wide range of pharmaceutical drugs for all Australians to help them afford standard medications. The Pharmaceutical Benefits Schedule lists all the medicinal products available under the PBS and explains the uses for which they can be subsidised.

<b>Plain packaging</b>	The <i>Tobacco Plain Packaging Act 2011</i> requires all tobacco products manufactured or packaged in Australia for domestic consumption from 1 October 2012 to be in plain packaging, and all tobacco products to be sold in plain packaging by 1 December 2012.
<b>Population health</b>	Typically described as the organised response by society to protect and promote health, and to prevent illness, injury and disability. Population health activities generally focus on: prevention, promotion and protection rather than on treatment; populations rather than on individuals; and the factors and behaviours that cause illness. In this sense, often used synonymously with <b>public health</b> . Can also refer to the health of particular subpopulations, and comparisons of the health of different populations.
<b>Portfolio Additional Estimates Statements</b>	Statements prepared by portfolios to explain the Additional Estimates Budget appropriations in terms of outcomes and programs.
<b>Portfolio Budget Statements</b>	Statements prepared by portfolios to explain the Budget appropriations in terms of outcomes and programs.
<b>Prevalence</b>	The number or proportion (of cases, instances, and so forth) in a population at a given time. In relation to cancer, this refers to the number of people alive who had been diagnosed with cancer in a prescribed period (usually 1-, 5-, 10- or 26-years). Compare with <b>incidence</b> .
<b>Primary care</b>	Provides the patient with a broad spectrum of care, both preventive and curative, over a period of time and coordinates all of the care the person receives.
<b>Program/Programme</b>	A specific strategy, initiative or grouping of activities directed toward the achievement of Government policy or a common strategic objective. In 2015-16, the Department had 31 specific programs (see pages 34-35).
<b>Prostheses List</b>	Under the <i>Private Health Insurance Act 2007</i> , private health insurers are required to pay benefits for a range of prostheses that are provided as part of an episode of hospital treatment or hospital substitute treatment for which a patient has cover and for which a Medicare benefit is payable for the associated professional service. The types of products on the Prostheses List include cardiac pacemakers and defibrillators, cardiac stents, joint replacements and intraocular lenses, as well as human tissues such as human heart valves. The list does not include external limbs, external breast prostheses, wigs and other such devices. The Prostheses List contains prostheses and human tissue prostheses and the benefit to be paid by the private health insurers. The Prostheses List is published bi-annually.
<b>Prosthesis</b>	An artificial device that replaces a missing body part lost through trauma, disease, or congenital conditions.
<b>Public health</b>	Activities aimed at benefiting a population, with an emphasis on prevention, protection and health promotion as distinct from treatment tailored to individuals with symptoms. Examples include conduct of anti-smoking education campaigns, and screening for diseases such as cancer of the breast or cervix. See also <b>Population health</b> .

<b>Quality use of medicines</b>	<p>Quality use of medicines means:</p> <ul style="list-style-type: none"> <li>• selecting management options wisely;</li> <li>• choosing suitable medicines if a medicine is considered necessary; and</li> <li>• using medicines safely and effectively.</li> </ul> <p>This definition applies equally to decisions about medicine use by individuals and decisions that affect the health of the population.</p>
<b>Radiation oncology (radiotherapy)</b>	<p>The study and discipline of treating malignant disease with radiation. The treatment is referred to as radiotherapy or radiation therapy.</p>
<b>Registrar</b>	<p>Any person undertaking medical vocational training in a recognised medical specialty training program accredited by the Australian Medical Council.</p>
<b>Sexually transmissible infection (STI)</b>	<p>An infectious disease that can be passed to another person by sexual contact. Notable examples include chlamydia and gonorrhoea.</p>
<b>Stoma</b>	<p>Artificial body opening in the abdominal region, for the purpose of waste removal.</p>
<b>Tuberculosis</b>	<p>Tuberculosis is an infectious disease that damages people's lungs or other parts of the body and can cause serious illness and death. It is caused by the bacterium <i>Mycobacterium tuberculosis</i>. Tuberculosis is spread through the air when a person with the active disease coughs, sneezes or speaks, and other people nearby breathe in the bacteria.</p>
<b>Vaccination</b>	<p>The process of administering a vaccine to a person to produce immunity against infection. See <b>immunisation</b>.</p>
<b>Varicella (Chicken pox)</b>	<p>A very contagious disease. An affected child or adult may develop hundreds of itchy, fluid-filled blisters that burst and form crusts. Varicella is caused by a virus, varicella-zoster.</p>
<b>World Health Organization (WHO)</b>	<p>The World Health Organization is a specialised agency of the United Nations. Its primary role is to direct and coordinate international health within the United Nations' system. The WHO has 194 member states including Australia.</p>
<b>Zika virus</b>	<p>A flavivirus, closely related to dengue. It is transmitted to humans primarily through the bite of certain infected <i>Aedes</i> species mosquitoes.</p>

# Index

2015 Annual Red Tape Reduction Report, 147

## A

abbreviations, 448–451

Aboriginal and Torres Strait Islander Flexible Aged Care Program, 208

Aboriginal and Torres Strait Islander Health (Program 5.3)

analysis of performance, 113–116  
budgeted expenses and resources, 122  
objectives, 108

Aboriginal and Torres Strait Islander peoples

aged care, 196, 201, 208, 209–210, 217

cancer screening programs, 47, 51

child and maternal health, 115–116

child mortality, 5, 107, 113, 116

childhood immunisation, 45, 61, 63

chronic diseases, 114–115

Closing the Gap, 106, 107, 113, 114

cord blood collection, 145

dementia care, 217

health checks, 114

health improvements, 5

hepatitis A vaccine, 61

life expectancy, 5, 114

pneumococcal vaccine, 61

reducing smoking rates, 45, 56, 57, 59, 113

staff numbers, 256, 260

trachoma, 113

workforce initiatives, 248–249

workforce trainees, 246

*Accelerating Growth in Organ and Tissue Donation for Transplantation*, 144

Access and Information (Program 11.1)

analysis of performance, 197–201

budgeted expenses and resources, 219

objectives, 196

Access to Medical and Dental Services (Outcome 3)

analysis of performance, 82

budgeted expenses and resources, 99–101

key community benefits, 83

looking ahead, 84

performance criteria summary, 83

program performance, 85–98

programs and objectives, 34, 84–85

Access to Pharmaceutical Services (Outcome 2)

analysis of performance, 66

budgeted expenses and resources, 80–81

key community benefits, 67

looking ahead, 68

performance criteria summary, 67

program performance, 69–79

programs and objectives, 34, 68

Accessibility Action Plan, 277

accidents *see* notifiable incidents

accountability and risk management, 230–231

accountability responsibilities, financial, 242

accreditation for pathology laboratories, 92

acronyms, 448–451

Acute Care (Outcome 4)

analysis of performance, 102

budgeted expenses and resources, 105

key community benefits, 103

looking ahead, 103

performance criteria summary, 103

program performance, 104–105

programs and objectives, 34, 103

administered expenses, 16, 17

Administrative Appeals Tribunals, 239

Administrative Arrangements Orders, 27

advertising and market research, 290–293

*Aedes aegypti* (mosquito), 8

*Aedes albopictus* (mosquito), 8, 175, 181

after-hours primary health care, 107, 111, 112

aged care

Community Visitors Scheme, 212

culturally appropriate care, 218

and dementia, 13, 215–217

home care, 204–207

home support services, 201–203

residential care, 208–211

Residential Medication Management Review, 71

Machinery of Government changes, 6, 27, 257

risk management of providers, 212–214

workforce training, 197, 199, 200, 281

*see also* My Aged Care

*Aged Care Act 1997*, 213

Aged Care Approvals Round, 209, 211

Aged Care Assessment Program, 200–201

Aged Care Assessment Teams, 200, 201, 207

Aged Care Complaints Commissioner, 27, 28, 214–215

Aged Care Complaints Scheme, 214–215

Aged Care Funding Instrument, 212

Aged Care Pricing Commissioner, 27, 28

- Aged Care Road Map, 6
- Ageing and Aged Care (Outcome 11)
- analysis of performance, 194
  - budgeted expenses and resources, 219–221
  - key community benefits, 195
  - looking ahead, 196
  - performance criteria summary, 195
  - program performance, 197–218
  - programs and objectives, 35, 196
- Ageing and Service Improvement (Program 11.6)
- analysis of performance, 215–218
  - budgeted expenses and resources, 220
  - objectives, 196
- agricultural and veterinary chemicals, 157 *see also* industrial chemicals
- aids and appliances, 76–79
- airports preparedness for health emergencies, 182
- alcohol consumption, reducing harm, 58
- Alzheimer's Australia, 13 *see also* dementia
- An invitation that could save your life* campaign, 52
- ANAO *see* Australian National Audit Office
- Annual Performance Statements
- structure and key, 40–43
  - see also by name of Outcome or Program*
- anti-doping measures, 185, 186, 191, 192
- antimicrobial resistance, 7, 10–11, 174, 175, 176, 177–178, 181–182
- Antimicrobial Use and Resistance in Australia (AURA), 10, 181–182
- Approved Pathology Laboratory, 92
- approved suppliers of medicines, 70
- APS Gender Equality Strategy: Balancing the Future*, 248
- As One: Australian Public Service Disability Employment Strategy*, 277
- Asia-Pacific Economic Cooperation (APEC) Health Working Group, 139
- asset management, 243
- Assistance with Care and Housing for the Aged Program, 201
- asthma, 47, 49
- audit and fraud control, 232
- Audit and Risk Committee, 228–230, 232
- Auditor-General *see* Australian National Audit Office
- audits
- Australian National Audit Office reports, 232, 234–236
  - Comcare, 273
  - health provider compliance, 404–406
  - Medicare program, 85, 87
- AURA 2016: first Australian report on antimicrobial use and resistance in human health*, 178
- Australia Day Awards, 251
- Australian Aged Care Quality Agency, 27, 36
- Australian Atlas of Healthcare Variation, 142
- Australian Bone Marrow Donor Registry, 145
- Australian Childhood Immunisation Register, 46, 60
- Australian Commission for eHealth, 136
- Australian Commission on Safety and Quality in Health Care, 36, 178
- Australian Digital Health Agency, 28, 130, 131, 133, 136
- annual report, 424–437
  - Board, 426–428
  - establishment and role, 425–426
  - financial management, 430–433
  - financial statement, 434–437
  - organisational structure, 429
  - performance, 430
- Australian General Practice Training Program, 169
- Australian Government Cost Recovery Guidelines, 388
- Australian Health Ministers' Advisory Council, 137
- Australian Immunisation Register, 46, 60
- Australian Information Commissioner decisions, 240
- Australian Institute of Health and Welfare, 36
- Australian Inventory of Chemical Substances, 154, 396–397
- Australian Medical Research Advisory Board, 132, 139, 141
- Australian Medical Research and Innovation Strategy, 130, 139, 141
- Australian National Audit Office
- access clauses, 245
  - audits, 232, 234–236
- Australian National Diabetes Strategy 2016–2020*, 47, 49
- Australian National Drug Strategy Household Survey, 46
- Australian National Preventive Health Agency financial statements, 410–423
- Australian Nurse Family Partnership Program, 116
- Australian Organ and Tissue Donation and Transplantation Authority, 36
- Australian Organ Donor Register, 144
- Australian Pesticides and Veterinary Medicines Authority, 157
- Australian Prescriber*, 141
- Australian Prudential Regulation Authority, 28, 128
- Australian Radiation Protection and Nuclear Safety Agency, 36
- Australian Sports Anti-Doping Authority, 36, 186
- Australian Sports Commission, 36, 186, 187
- Australian Sports Foundation, 37, 186, 187
- Australian Workplace Agreements, 252
- Australia's notifiable disease status, 2014: Annual Report of the National Diseases Surveillance System*, 180
- Australia's Winning Edge, 187
- Authority Required PBS Listings, 74

**B**

- Baggoley, Chris, 20, 21
  - Chief Medical Officer's report, 8–13
- Behaviours in Action*, 15, 16, 247
- billing practices, 403
- Biomedical Translation Fund, 141
- Biosecurity Act 2015*, 9
- Biosecurity and Emergency Response (Outcome 9)
  - analysis of performance, 174
  - budgeted expenses and resources, 183
  - key community benefits, 175
  - looking ahead, 176
  - performance criteria summary, 175
  - program performance, 177–182
  - programs and objectives, 35, 176
- Birch, Jim, 426
- Birch, Kassmena, 251
- BlakChat, 249
- blood and blood products, 146
- Blood and Organ Donation (Program 7.6)
  - analysis of performance, 144–146
  - budgeted expenses and resources, 162
  - objectives, 133
- blood-borne viruses, 47, 54
- Bonded Medical Program, 167
- bowel cancer screening, 45, 46, 47, 51
- Bowles, Martin, 20, 21
  - Secretary's review of year, 4–7
- Bransby, Robert, 426
- Break the Chain* campaign, 57
- breast cancer, 47, 52–53
  - breast prostheses, 87, 89
  - medicines, 66
- breast care nurses, 52
- BreastScreen Australia, 47, 52–53, 290
- budgeted expenses and resources
  - Outcome 1: Population Health, 64–65
  - Outcome 2: Access to Pharmaceutical Services, 80–81
  - Outcome 3: Access to Medical and Dental Services, 99–101
  - Outcome 4: Acute Care, 105
  - Outcome 5: Primary Health Care, 122–123
  - Outcome 6: Private Health, 129
  - Outcome 7: Health Infrastructure, Regulation, Safety and Quality, 161–163
  - Outcome 8: Health Workforce Capacity, 173
  - Outcome 9: Biosecurity and Emergency Response, 183
  - Outcome 10: Sport and Recreation, 193
  - Outcome 11: Ageing and Aged Care, 219–221
- business planning and performance reporting framework, 231

**C**

- cancer
  - medicines, 66
  - Optimal Cancer Care Pathways, 11
  - screening programs, 45, 46, 47, 51–53
- Cancer Australia, 37
- capabilities, Department, 27
- capital works, 208
- Carer Recognition Act 2010*, 276
  - compliance report, 279–281
- carers, 276, 279–281
- Carers Australia, 280
- Cartagena Protocol on Biosafety, 160
- cervical cancer screening, 46, 47, 53
- Champions in the workplace, 250, 276, 277
- Charter of Rights and Responsibilities, 206
- chemical safety, 153–158
- chemicals see industrial chemicals
- Chew, Eleanor, 426–427
- Chief Medical Officer's report, 8–13
- Chief Operating Officer's report, 14–17
- chikungunya, 8
- Child and Adult Public Dental Scheme, 84, 97
- child and maternal health, 115–116
- Child Dental Benefits Schedule, 97, 235, 405
- child mortality, 5, 107, 113, 116
- children
  - dental services, 84, 97
  - immunisation, 11, 45, 46, 60–63
- Choice in Home Care, 196
- chronic diseases, 47, 49
  - in Aboriginal and Torres Strait Islander peoples, 114–115
  - managing, 4–5, 106
  - see also diabetes; Health Care Homes
- clinical best practice, 142
- Clinical Intervention Program (pharmacy), 70
- clinical training, 168
- Clinical Training Funding program, 171, 172
- clinical trials, 131
- Clinical Trials Framework for Action*, 140
- clinical trials processes, 140
- Closing the Gap, 106, 107, 113, 114
- Comcare audit, 273
- Comcare claims, 274
- Comcover Risk Management Benchmarking Survey, 231
- Committee of Australian Sport and Recreation Officials, 187
- common law contracts, 252
- Commonwealth Contracting Suite, 245
- Commonwealth Director of Public Prosecutions, 85, 403, 408–409
- Commonwealth Disability Strategy, 278
- Commonwealth Games 2018, 186, 188–189

- Commonwealth Home and Community Care Program, 201
- Commonwealth Home Support Program, 196, 197, 201–203
- Commonwealth Medical Internships Program, 170
- Commonwealth Ombudsman, 241
- Commonwealth Procurement Rules, 244
- Commonwealth v Sanofi and Wyeth, 239
- communicable diseases, 7, 54, 177, 179, 180
- Communicable Diseases Intelligence*, 180
- community pharmacies, 70, 71
- Community Pharmacy and Pharmaceutical Awareness (Program 2.1)
- analysis of performance, 69–71
  - budgeted expenses and resources, 80
  - objectives, 68
- Community Service Obligation Funding Pool, 69, 71
- Community Visitors Scheme, 211, 212
- Competitive Aged Care Approvals Round, 208
- complementary medicines, 148
- compliance reporting, 232
- Concussion in Sport website, 187
- Conlon, Kathleen, 229
- consultants, 243–244
- consumer-directed care, 6, 195, 204–207
- contact details, ii
- contact tracing of travellers, 180
- Contributing Lives, Thriving Communities*, 117, 281
- controlled substances, 150
- Co-payment \$1 discount measure, 69
- cord blood collection, 144–145
- Cormack, Mark, 20, 22
- corporate governance, 15, 226–233
- Corporate Plan 2015-16*, 40, 227, 228, 230
- Corporate Plan 2016-17*, I, 15, 26, 230, 231
- corporate services, 14–17
- Council of Australian Governments Health Council, 137
- Culturally and Linguistically Diverse (CALD) people
- aged care, 212, 218, 248, 281
  - cancer screening programs, 47, 51, 52
  - working group, 281
- D**
- data analytics, 6
- Date of Supply dataset, 69
- Day Therapy Centres Program, 201
- debts raised, 407
- dementia, 12–13, 215–217, 281
- Dementia and Aged Care Services Fund, 216, 217
- Dementia Behaviour Management Advisory Services, 13, 215, 216, 217, 281
- Dementia Care Essentials, 216
- Dementia Training Program, 215, 281
- Dementia Training Study Centres, 216
- dengue, 8
- Dental Benefits Act 2008* review, 97
- Dental Relocation Infrastructure Support Scheme, 171
- dental services, 83, 84, 97–98, 171–172
- Dental Services (Program 3.6)
- analysis of performance, 97–98
  - budgeted expenses and resources, 100
  - objectives, 85
- Department of Health
- corporate governance, 15, 226–233
  - Executive, 20–25
  - overview of, 26–28
  - see also Outcomes; Portfolio
- Department of Human Services, 89, 93
- Deveny, Elizabeth, 427
- diabetes, 47, 49, 69, 70, 76, 77–78, 114
- Diabetes Australia, 77
- diagnostic imaging, 84
- Diagnostic Imaging Accreditation Scheme review, 82, 90
- digital health capability, 28, 130, 131, 133–136 see also Australian Digital Health Agency
- Digital Transformation Agenda, 6
- Digital Transition Policy, 236
- diphtheria-tetanus-acellular-pertussis (DTPa) vaccine, 61
- Director of Professional Services Review, 85, 406
- disability, 276–278
- Disability and Carers Network, 279
- Disaster Health Care Assistance Schemes, 87, 89
- disease control and prevention
- hepatitis C, 9–10
  - mosquito-borne diseases, 8, 175, 181
- diversity in the workplace, 248–251
- Domestic Health Response Plan for Chemical, Biological, Radiological and Nuclear Incidents of National Consequence, 179
- Don't Make Smokes Your Story* campaign, 45, 56, 57, 59
- drowning prevention, 185, 186, 190
- Drug Strategy (Program 1.2)
- analysis of performance, 56–59
  - budgeted expenses and resources, 64
  - objectives, 46
- Drug Utilisation Sub-Committee (PBAC), 389
- E**
- Early Intervention policy, 272, 274
- Ebola, 7, 12
- ecologically sustainable development and environmental performance, 282–289
- Economics Sub-Committee (PBAC), 389
- eHealth (Program 7.1)
- analysis of performance, 133–136
  - budgeted expenses and resources, 161
  - objectives, 132
  - see also Australian Digital Health Agency
- elective surgery, 102, 103, 104–105

emergency preparedness, 175, 176, 177, 179, 180  
 emerging infectious diseases, 12  
 Employee Assistance Program, 276  
 employment arrangements, 251–252, 262–263  
 energy consumption and efficiency, 285–286  
 Energy Efficiency in Government Operations Policy, 284  
 energy performance standards, 284  
 Enterprise Agreement 2016–2019, 251, 255, 263  
 Enterprise Risk Framework, 15  
 entity resource statement, 222–223  
*Environment Protection and Biodiversity Conservation Act 1999* compliance, 282–286  
 environmental performance, 282–289  
 Epidermolysis Bullosa Dressing Scheme, 76, 78, 79  
 ergonomic assessments, 272, 273  
 Essential Vaccines Procurement Strategy, 60, 61  
 ethical standards, 255  
 Exceptional Claims Scheme, 93  
 Executive, 20–25  
 Executive Committee, 227  
 exempt contracts, 245  
 Exercise CURIEosity, 179  
*Expenditure and prescriptions twelve months to 30 June 2015*, 69  
 Expert Review of Medicines and Medical Devices Regulation, 148  
 External Breast Prostheses Reimbursement Program, 89  
 external scrutiny, 234–241

**F**

Federal Register of Legislation, 149, 155  
 Fifth Community Pharmacy Agreement, 69, 236  
 Fifth National Mental Health Plan, 117, 118  
 Finance and Resources Committee, 227, 242  
 financial management, 17, 242–245  
     Chief Operating Officer's report, 14–17  
     National Industrial Chemicals Notification and Assessment Scheme, 402  
 financial statements  
     Australian Digital Health Agency, 434–437  
     Australian National Preventive Health Agency, 410–423  
     Department of Health, 17, 296–385  
     entity resource statement, 222–223  
     process, 296  
     see also budgeted expenses and resources  
*First Activity Report on Commercially Sponsored Clinical Trials in Australian Public Health Organisations*, 140  
 follow-me printing, 288  
 food regulatory policy, 47, 50  
 Food Standards Australia New Zealand, 37  
*Fourth National Hepatitis C Strategy*, 9  
*Framework for National Aggregate Statistics for Clinical Trials*, 140

fraud investigations, 407  
 fraud minimisation, 232–233  
*Fraud Prevention and Compliance—improve billing practices within public hospitals*, 403  
 freedom of information, 240

**G**

*Gene Technology Act 2000*, 283  
*Gene Technology Regulations 2001*, 158  
 Gene Technology Regulator, 28, 149, 158–160, 283  
 General Practice Rural Incentives Program, 5, 169  
 General Practitioners Antimicrobial Stewardship Program Study, 11  
 General Purpose Financial Reports, 212  
 genetically modified organisms, 149, 159–160, 283  
*Girls Make Your Move* campaign, 6, 45, 48, 290  
 global health issues, 7, 138–139  
 Global Strategy and Plan of Action on Ageing and Health, 139  
 glossary, 452–457  
 Good Manufacturing Practice, 151, 152  
 governance committee structure, 226  
 grants, 16, 244  
 Green Car Challenge, 288  
 Green Lease Schedule, 284  
*Growing evidence of an emerging tick-borne disease that causes a Lyme like illness for many Australian patients*, 10

**H**

*headspace* centres, 117, 118  
 Health and Hospitals Fund grants, 143  
 Health and Wellbeing Framework, 272, 274  
 Health Capability Program, 7  
 Health Care Homes, 5, 107, 108, 111, 112  
 health data, 6  
 health delegations from overseas, 138  
 Health Emergency Planning and Response (Program 9.1)  
     analysis of performance, 177–182  
     budgeted expenses and resources, 183  
     objectives, 176  
 health funds' prudential obligations, 128  
 Health Information (Program 7.2)  
     analysis of performance, 137  
     budgeted expenses and resources, 161  
     objectives, 132  
 Health Infrastructure (Program 7.5)  
     analysis of performance, 143–144  
     budgeted expenses and resources, 162  
     objectives, 132  
 Health Infrastructure, Regulation, Safety and Quality (Outcome 7)  
     analysis of performance, 130  
     budgeted expenses and resources, 161–163  
     key community benefits, 131  
     looking ahead, 132



- performance criteria summary, 131
  - program performance, 133–160
  - programs and objectives, 35, 132–133
  - Health Performance Framework 2017, 114
  - Health Pride Network, 250
  - Health Professional Guidelines, 404
  - health provider compliance, 85, 87, 404
    - audits, 404–406
    - Hotline, 408
    - Report, 403–409
    - tip-offs, 408
  - Health Star Rating system, 290, 291, 293, 446
  - Health State Network, 7, 15
  - Health Workforce Capacity (Outcome 8)
    - analysis of performance, 164
    - budgeted expenses and resources, 173
    - key community benefits, 165
    - looking ahead, 166
    - performance criteria summary, 165
    - program performance, 167–172
    - programs and objectives, 35, 166
  - Health Workforce Scholarship Program, 167
  - health workforce training, 5, 165
    - aged care, 197, 199, 200, 281
    - dementia, 215, 216, 281
    - general practitioners, 169
    - nurses and nurse-led programs, 165, 168
    - regional, rural and remote area placements, 164–170
    - scholarships, 167
    - specialists, 169
  - healthcare variations, 142
  - Healthier Medicare — enhanced Medicare compliance program*, 404
  - hearing aid fittings, 96
  - Hearing Loss Prevention Program, 95
  - Hearing Services Program, 84
  - Hearing Services (Program 3.5)
    - analysis of performance, 95–96
    - budgeted expenses and resources, 100
    - objectives, 85
  - hearing services vouchers, 83, 96
  - hepatitis A vaccine, 61
  - hepatitis B, 54
  - hepatitis C, 5, 9–10, 54
    - new medicines, 67, 72
  - High Cost Claims Scheme, 93
  - history of Department, 26
  - HIV (human immunodeficiency virus), 54
  - Home Care Packages (aged care), 6, 204–207
  - Home Care (Program 11.3)
    - analysis of performance, 204–207
    - budgeted expenses and resources, 219
    - objectives, 196
  - Home Medicines Review Program, 70
  - Home Support (Program 11.2)
    - analysis of performance, 201–203
    - budgeted expenses and resources, 219
    - objectives, 196
  - home support services, 195
  - Hospital Medication Chart, 68
  - human papillomavirus (HPV)
    - test for, 53
    - vaccination program, 60, 61
    - see also cervical cancer screening
  - human resources see people management; staff
- I**
- ICARE principles, 27
  - ice (illicit drug), 56, 58
  - illicit drugs, 56, 58–59
  - Illicit Drugs in Sport, 6, 191
  - immunisation, 11, 45, 46
  - Immunisation (Program 1.3)
    - analysis of performance, 60–63
    - budgeted expenses and resources, 64
    - objectives, 46
  - Implementing the Deregulation Agenda: Cutting Red Tape, 234, 236
  - Improving the Regulation of Therapeutic Goods in Australia*, 148
  - Independent Hospital Pricing Authority, 28, 37
  - Indigenous Australians' Health Programme, 16, 113, 114 see also Aboriginal and Torres Strait Islander peoples
  - Indigenous Entry Level Program, 249
  - Indigenous Procurement Policy, 245
  - individual determinations under s24 of the *Public Service Act 1999*, 252, 262
  - industrial chemicals, 148, 153–158
  - Industrial Chemicals (Notification and Assessment) Act 1989*, 156, 158, 283, 394
  - infectious diseases, 12, 72
  - influenza, 11
  - Information and Communication Technology Sustainability Plan, 287
  - infrastructure see Health Infrastructure (Program 7.5)
  - Innovation and Competitiveness agenda, 147
  - Innovation Australia, 141
  - Insulin Pump Program, 76, 78 see also diabetes
  - insurance premiums, private health, 127
  - insurance products for medical professionals, 93–94
  - Integrated Rural Training Pipeline Initiative*, 166
  - integrity in sport, 6, 185, 186, 191–192
  - internal audit arrangements, 232–233
  - internal reviews, 406
  - International Coalition of Medicines Regulatory Authorities, 152
  - international engagement, 131, 132
    - anti-doping measures, 191
    - antimicrobial resistance, 178
    - chemical safety, 154–155, 156
    - genetically modified organism regulation, 160
    - health emergency preparedness, 180

therapeutic goods regulation, 152  
 see also World Health Organization  
 International Engagement Strategy 2013–2015 (TGA), 152  
 International Health Regulations (2005), 180, 182  
 International Medical Devices Regulators' Forum, 152  
 International Policy Engagement (Program 7.3)  
     analysis of performance, 138–139  
     budgeted expenses and resources, 161  
     objectives, 132  
 internships, 170  
 Inventory Multi-tiered Assessment and Prioritisation framework, 154, 158, 399–400

**J**  
 Joint Committee of Public Accounts and Audit, 236, 275  
 judicial decisions, 239–240  
 Jurisdictional Blood Committee Strategic Plan, 144

**K**  
 'Keep Sport Honest' education module, 191  
 key community benefits see 'key community benefits' under each Outcome  
 KidsMatter Primary, 117, 118–119

**L**  
 leadership development, 15, 247, 253 see also people management  
 Learning and Development Strategy 2016–2019, 252–253  
 Lesbian, Gay, Bisexual, Transgender and Intersex (LGBTI) people  
     aged care support, 205, 212  
     workforce initiatives, 250  
     working group, 281  
 letter of transmittal, 1  
 Ley, Sussan, 27, 32  
 life expectancy of Indigenous Australians, 5, 114  
 Life Saving Drugs Program, 67, 74, 75–76  
 list of requirements, 440–447  
 Lyme disease, 10

**M**  
 Machinery of Government changes, 27, 257, 403  
 Madden, Paul, 20, 23, 427  
 magnetic resonance imaging (MRI), 84  
 malaria, 8  
 market research and advertising, 290–293  
 mastectomy, 87, 89  
 match-fixing, 191  
 McCarthy, Margot, 20, 23  
 McGrath, Lyn, 427  
 McGrath Foundation, 52

medical devices, 150  
 Medical Indemnity (Program 3.4)  
     analysis of performance, 93–94  
     budgeted expenses and resources, 100  
     objectives, 85  
 Medical Insurance Group Australia, 94  
 Medical Research Future Fund, 132, 139  
*Medical Research Future Fund Act 2015*, 141  
 Medical Research Future Fund Advisory Board, 130  
 Medical Rural Bonded Scholarship Scheme, 167  
 Medical Services Advisory Committee, 83, 84, 85, 86  
 Medical Treatment Overseas Program, 87, 88  
 Medicare Benefits Schedule (MBS), 83  
     audits and reviews, 85, 87, 405  
     billing in public hospitals, 403  
     health provider compliance, 404  
     pathology services, 84, 90, 91–92  
     Review Taskforce, 5, 82, 83, 84, 85, 86, 91  
     sustainability, 86  
 Medicare Locals, 5  
 Medicare Participation Review Committees, 408  
 Medicare Provider Compliance, 27, 257, 403  
 Medicare Services (Program 3.1)  
     analysis of performance, 85–87  
     budgeted expenses and resources, 99  
     objectives, 84  
 Medication Management Review, 70–71  
 medicinal cannabis, 148  
 medicines  
     access to, 66, 67, 70, 71  
     cost of, 71  
     price disclosure policy, 66, 73  
     reviews of, 72  
     see also Life Saving Drugs Program; NPS MedicineWise; Pharmaceutical Benefits Scheme  
 Medicines and Medical Devices Regulation, 152, 153  
 Medscheck/Diabetes Medscheck Program, 70  
 melanoma, 66  
 Mental Health (Program 5.4)  
     analysis of performance, 117–119  
     budgeted expenses and resources, 122  
     objectives, 108  
 mental health services, 106, 108  
     headspace centres, 117, 118  
     review, 5, 117, 281  
 Mersey Community Hospital, Tasmania, 104  
 Middle East Respiratory Syndrome Coronavirus, 7, 12, 180  
 Midwife Professional Indemnity Scheme, 93, 94  
 Ministerial Dementia Forum, 13  
 ministerial responsibilities, 32–33  
 Modified Monash Model, 5, 169, 171  
 Moo, Stephen, 427  
 Morison, Jenny, 229  
 mortality  
     chronic diseases, 115

- Indigenous children, 5, 107, 113, 116
  - mosquito control, 175, 181
  - mosquito-borne diseases, 8–9, 174
  - Multicultural Forums, 248
  - Multi-Purpose Services (aged care), 211
  - My Aged Care, 195, 197, 281
    - assessments completed, 200, 201
    - client registrations, 199
    - Contact Centre, 198, 199
    - culturally appropriate care, 218
    - data transition, 201
    - health workforce training, 197, 199, 200, 281
    - website, 198
  - My Health Record, 6, 132, 133–136, 425
  - My QuitBuddy* mobile app, 57, 59
- N**
- NABERS energy ratings, 284
  - NAIDOC Week, 249
  - Narcotic Drugs Act 1967*, 148
  - Nash, Fiona, 27, 32
  - National Aboriginal and Torres Strait Islander Flexible Aged Care Program, 209–210, 217
  - National Aboriginal and Torres Strait Islander Health Plan 2013–2023, 5, 113, 114
  - National Aboriginal and Torres Strait Islander Staff Network, 249
  - National Acoustic Laboratories, 96
  - National Aged Care Alliance, 202
  - National Anti-Doping Framework, 192
  - National Antimicrobial Resistance Implementation Plan, 177, 181–182
  - National Antimicrobial Resistance Strategy 2015–2019*, 10–11, 178
  - National Association of Testing Authorities, 92
  - National Asthma Strategy, 47, 49
  - National Blood Agreement, 144, 146
  - National Blood Authority, 37
  - National Blood-borne Viruses (BBV) and Sexually Transmissible Infections (STI) Strategies 2014–2017, 47, 54
  - National Bowel Cancer Screening Program, 45, 46, 47, 51, 290
  - National Cancer Expert Reference Group, 11
  - National Cancer Screening Register, 46
  - National Carers Week, 276, 279
  - National Cervical Screening Program, 46, 47, 53
  - National Cord Blood Collection Network, 145
  - National Critical Care and Trauma Response Centre, 176
  - National Dementia Friendly Resource Hub, 13
  - National Dementia Support Program, 216
  - National Diabetes Services Scheme, 69, 76, 77
  - National Disability Insurance Scheme hearing services transition, 84, 95
  - National Disability Strategy 2010–2020, 278
  - National Drug Strategy Household Survey, 59
  - National Drugs Campaign, 58, 290
  - National E-Health Transition Authority, 28, 133, 425
    - see also* Australian Digital Health Agency
    - National Framework for Action on Dementia 2015–2019*, 12–13
  - National Framework for Health Services for Aboriginal and Torres Strait Islander Children and Families, 114
  - National Health Act 1953*, 388
  - National Health and Medical Research Council
    - Aboriginal and Torres Strait Islander health, 114
    - dementia research, 13
    - hearing research, 95, 96
    - Portfolio entity, 37
  - national health emergency preparedness, 175, 176, 177, 179, 180
  - National Health Emergency Response Arrangements, 179
  - National Health Funding Body, 37
  - National Health Funding Pool Administrator, 28
  - National Health Performance Authority, 28, 37
  - National Health Security Act 2007*, 180
  - National Health Survey: First Results, 2014–15*, 59
  - National Ice Action Strategy, 56, 58
  - National Ice Taskforce Final Report, 56, 58
  - National Immunisation Program, 11, 45, 60, 61
  - National Immunisation Strategy 2013–2018, 60
  - National Incident Room, 180
  - National Industrial Chemicals Notification and Assessment Scheme
    - Australian Inventory of Chemical Substances, 396–397
    - chemical assessment reports, 148, 153
    - compliance monitoring, 395
    - Director's report, 394–402
    - ecologically sustainable development principles, 283
    - existing chemicals assessments, 399–400
    - financial performance, 402
    - IMAP assessments, 154, 158
    - international engagement, 154–155, 156, 401
    - new industrial chemicals, 157, 158, 398–399
    - reforms, 156, 400–401
    - registered companies, 155, 395, 396
    - stakeholder advice, 401
    - statutory office holders, 28
    - website, 401
  - National Innovation and Science Agenda, 141
  - National Medical Stockpile, 176, 177, 179, 182
  - National Mental Health Commission, 5, 37, 117
  - National Notifiable Diseases Surveillance System, 180
  - National Palliative Care Strategy 2010, 54, 280
  - National Partnership Agreement on Essential Vaccines, 61
  - National Partnership Agreement on Treating More Public Dental Patients, 83, 97, 98

- National Pathology Accreditation Advisory Council, 92
- National Practice Standards for Hearing Care Practitioners*, 95
- National Prescribing Service Ltd *see* NPS MedicineWise
- National Recreation Safety Program, 190
- National Respite for Carers Program, 201
- National Sport and Active Recreation Policy Framework, 187
- National Staff Participation Forum, 255
- National Strategic Framework for Chronic Conditions, 47, 49
- National Supply Plan and Budget (blood and blood products), 146
- National Tobacco Campaign, 57, 59, 290 *see also* tobacco
- National Work Health Safety Committee, 273
- Needle and Syringe Program, 10
- Netball World Cup, 6, 185, 186, 188–190
- New Directions: Mothers and Babies Services, 115
- Newell, Stephanie, 428
- Ng, Bennie, 428
- No Jab, No Pay*, 61
- Norfolk Island residents, 196
- notifiable incidents, 275
- NPS MedicineWise, 141–142
- nurses and nurse-led programs, 52, 94, 165, 168
- Nursing and Midwifery Board of Australia, 94
- O**
- occupational health and safety *see* work health and safety
- OECD *see* Organisation for Economic Co-operation and Development (OECD)
- Office of Chemical Safety, 156
- Office of Drug Control, 150
- Office of the Commonwealth Ombudsman, 28
- Office of the Gene Technology Regulator *see* Gene Technology Regulator
- Optimal Cancer Care Pathways, 11
- optometry services, 119, 121
- Oral Health Therapist Graduate Year Programme, 172
- Organ and Tissue Authority, 144
- organ and tissue donation, 144–146
- Organisation for Economic Co-operation and Development (OECD)
- collaboration to assess industrial chemicals, 154
  - Health Committee, 139
  - Working Group on the Harmonisation of Regulatory Oversight in Biotechnology, 160
- organisational capability, 14–15
- organisational structure, 29–31
- Our Behaviours in Action*, 7, 27, 253
- Outcomes
- Department-specific outcomes, 34–35, 42–43
  - Portfolio entity-specific outcomes, 36–37
  - Outcome 1 *see* Population Health (Outcome 1)
  - Outcome 2 *see* Access to Pharmaceutical Services (Outcome 2)
  - Outcome 3 *see* Access to Medical and Dental Services (Outcome 3)
  - Outcome 4 *see* Acute Care (Outcome 4)
  - Outcome 5 *see* Primary Health Care (Outcome 5)
  - Outcome 6 *see* Private Health (Outcome 6)
  - Outcome 7 *see* Health Infrastructure, Regulation, Safety and Quality (Outcome 7)
  - Outcome 8 *see* Health Workforce Capacity (Outcome 8)
  - Outcome 9 *see* Biosecurity and Emergency Response (Outcome 9)
  - Outcome 10 *see* Sport and Recreation (Outcome 10)
  - Outcome 11 *see* Ageing and Aged Care (Outcome 11)
- outlook *see* 'looking ahead' *under each Outcome*
- overseas travel, medical support, 87, 88
- P**
- Pacific Heads of Health Meeting, 139
- palliative care, 54–55, 280
- Pap test, 53 *see also* cervical cancer screening
- Parliamentary Committee inquiries, 238–239
- parliamentary scrutiny, 237–239
- Partners In Culturally Appropriate Care, 218
- Pathology and Diagnostic Imaging Services and Radiation Oncology (Program 3.3)
- analysis of performance, 90–92
  - budgeted expenses and resources, 99
  - objectives, 84
- Pathology Clinical Committee, 91
- pathology services, 84, 90, 91–92
- Pathology Services Advisory Committee, 91
- PBS *see* Pharmaceutical Benefits Scheme
- Peddle, Steve, 229
- People, Values and Capability Committee, 228
- People Assist referrals, 276
- people management, 246–255 *see also* staff
- People Strategy 2016–20, 16, 246–247, 256
- Performance Development Scheme, 247
- performance pay, 252, 271
- Performance Statistic Report (TGA), 149
- Personally Controlled Electronic Health Record review, 133, 425
- pertussis (whooping cough) booster vaccine, 11
- Pharmaceutical Benefits Advisory Committee, 67, 68, 73
- applications and submissions, 391–393
  - cost recovery, 388–389
  - processes leading to PBAC consideration, annual report on, 388–393

- requirements under *National Health Act 1953*, 390
- roles, 389
- sub-committees, 389
- Pharmaceutical Benefits Scheme, 66
  - audits, 405
  - hepatitis C medicines, 9, 72
  - innovation and efficiencies, 68
  - medicines listed (number), 66, 67
  - new medicine submissions, 73
  - published data, 69–70
  - reforms, 5
  - sustainability of, 73
  - see also NPS MedicineWise; Pharmaceutical Benefits Advisory Committee
- pharmaceuticals, reducing misuse, 58
- Pharmaceuticals and Pharmaceutical Services (Program 2.2)
  - analysis of performance, 72–74
  - budgeted expenses and resources, 80
  - objectives, 68
- Pharmacy Administration, Handling and Infrastructure fee, 69
- Pharmacy Trial Program, 68, 69
- PharmCIS, 69
- Philip Morris Asia legal challenge, 56, 240
- physical activity see sport and recreation
- Play.Sport.Australia* strategy, 187
- pneumococcal vaccine, 61
- Population Health (Outcome 1)
  - analysis of performance, 44
  - budgeted expenses and resources, 64–65
  - key community benefits, 45
  - looking ahead, 46
  - performance criteria summary, 45
  - program performance, 47–63
  - programs and objectives, 34, 46
- Portfolio
  - entities, 28, 36–37
  - responsibilities, 27
  - structure, 28
- Portfolio Budget Statements, 1, 40
- Positive Choices web portal, 56, 58
- post-market reviews of PBS medicines, 74
- Practice Accreditation Standards, 90
- Practice Incentives Program, 108, 111
  - audits, 405
  - After Hours Incentive, 107, 111, 112
- Practice Nurse Incentive Program, 165, 168, 405
- Practitioner Review Program, 405–406
- Premium Support Scheme, 93–94
- price disclosure policy, 66, 73
- Pride in Diversity, 250
- Primary Care Financing, Quality and Access (Program 5.1)
  - analysis of performance, 108–110
  - budgeted expenses and resources, 122
  - objectives, 108
- Primary Care Practice Incentives (Program 5.2)
  - analysis of performance, 111–112
  - budgeted expenses and resources, 122
  - objectives, 108
- Primary Health Care Advisory Group, 107, 111
- Primary Health Care (Outcome 5)
  - analysis of performance, 106
  - budgeted expenses and resources, 122–123
  - key community benefits, 107
  - looking ahead, 108
  - performance criteria summary, 107
  - program performance, 108–121
  - programs and objectives, 35, 108
- Primary Health Care (Rural Health Services), 166
- primary health care system, 4–5
- Primary Health Networks, 5, 108–110, 118
- Priority Existing Chemical, 153
- Private Health Insurance Administration Council, 28, 128
- Private Health Insurance Ombudsman, 28
- Private Health Insurance (Program 6.1)
  - analysis of performance, 126–129
  - budgeted expenses and resources, 129
  - objectives, 126
- Private Health Ministerial Advisory Committee, 125
- Private Health (Outcome 6)
  - analysis of performance, 124
  - budgeted expenses and resources, 129
  - key community benefits, 125
  - looking ahead, 125
  - performance criteria summary, 125
  - program performance, 126–128
  - programs and objectives, 35, 126
- private hospital cover, 127
- Probity Checking training (sport), 192
- procurement, 244–245
- Professional Services Review, 37
- program performance see *specific names of programs*
- Project Agreement on Improving Trachoma Control Services for Indigenous Australians, 113
- property review, 17
- Prostheses List, 125, 126, 128
- Prostheses List Advisory Committee, 125
- providers of aged care, 204, 206, 207
  - compliance, 211, 212–214
- public dental services, 83, 84, 97–98, 171–172
- Public Governance, Performance and Accountability Act 2013* (PGPA Act), 26, 40, 230, 242, 296, 425, 435
- Public Health, Chronic Disease and Palliative Care (Program 1.1)
  - analysis of performance, 47–55
  - budgeted expenses and resources, 64
  - objectives, 46

*Public Health Emergency of International Concern*, 12  
 Public Hospitals and Information (Program 4.1)  
     analysis of performance, 104–105  
     budgeted expenses and resources, 105  
     objectives, 103  
 public hospitals funding, 5, 102, 103  
 purchasing, 244  
 purpose, about the Department, 26, 41

**Q**

quadrivalent influenza vaccines, 11  
 quality assurance measures *see* Health Infrastructure, Regulation, Safety and Quality (Outcome 7); Primary Care Financing, Quality and Access (Program 5.1)  
*Quality Principles for Hearing Care*, 95  
 Quality Use of Diagnostics, Therapeutics and Pathology Flexible Fund, 142  
*Quarantine Act 1908*, 9  
 Questions on Notice, 237  
*Quit for You, Quit for Two* campaign, 57  
 QuitNow website, 59

**R**

Radiation Oncology Health Program Grants Scheme, 90, 235  
 radiation oncology services, 90, 92  
 radiological emergency preparedness, 179  
*Rational Assessment of Drugs and Research*, 141  
*Rationalising and streamlining health programs*, 171  
 rebate for private health insurance, 124, 125, 126–127  
 Reciprocal Health Care Agreements, 87, 88  
 Reconciliation Action Plan, 248  
 Records Management in Health, 236  
 RecruitAbility Scheme, 277  
 red tape reduction, 74, 147  
 referrals (fraud), 408–409  
 regional, rural and remote communities  
     dental services, 171–172  
     health care, 106, 107, 119–121  
     health infrastructure, 132, 143, 144  
     health workforce, 164–170  
 Regional Assessment Services (aged care), 200  
 Regional Priority Round of Health and Hospitals Fund grants, 143  
 registrars, 165  
 regulation of health industry, 132  
 Regulator Performance Framework, 147  
 regulatory burden savings, 74, 147  
 Regulatory Policy (Program 7.7)  
     analysis of performance, 147–160  
     budgeted expenses and resources, 163  
     objectives, 133  
 research, hearing loss, 96  
 Research Capacity and Quality (Program 7.4)

    analysis of performance, 139–142  
     budgeted expenses and resources, 161  
     objectives, 132  
 residential aged care places (number), 209  
 Residential and Flexible Care (Program 11.4)  
     analysis of performance, 208–211  
     budgeted expenses and resources, 220  
     objectives, 196  
 Residential Medication Management Review, 71  
 Review of Mental Health Programmes and Services, 5, 117, 281  
 Risk Appetite Statement, 15  
 risk management, 15  
     aged care providers, 212–214  
     corporate governance, 231  
     genetically modified organisms, 159, 160  
 Royal Flying Doctor Service, 107, 119, 121  
 Rugby League World Cup 2017, 186, 188–189  
 Rural, Regional and Other Special Needs Building Fund, 208  
 Rural and Regional Health Australia website, 121  
 Rural and Regional Teaching Infrastructure Grants program, 132, 143, 144  
 Rural Clinical Training and Support Program, 168  
 Rural Health Commissioner, 166  
 Rural Health Multidisciplinary Training Program, 166, 168  
 Rural Health Outreach Fund, 107, 119, 120  
 Rural Health Services (Program 5.5)  
     analysis of performance, 119–121  
     budgeted expenses and resources, 123  
     objectives, 108

**S**

safety *see* snow safety; water safety; work health and safety  
*Safety, Rehabilitation and Compensation Act 1988*, 272  
 safety and quality in health care, 142  
 salaries *see under* staff  
 Saving Lives in the Water initiative, 190  
 scholarships, 167  
 seaports preparedness for health emergencies, 182  
 Secretary's review of year, 4–7  
 Senate committees, 237–239  
 Senate Estimates hearings, 237  
 Senior Executive Service (SES) staff  
     individual determinations, 252  
     leadership development, 253  
     numbers, 262  
     remuneration, 252, 268  
     women, 256  
 Senior Executive Service Roundtable on Reconciliation and Respect, 248  
 Service Development Assistance Panel, 217  
 Severe Behaviour Response Teams, 13, 215, 216, 217

- sexually transmissible infections, 47, 54
  - Shakespeare, Penny, 230
  - Short-Term Restorative Care Program, 208, 211
  - Sixth Community Pharmacy Agreement, 5, 69, 236
  - Skerritt, John, 20, 24, 230
  - Small Business Engagement Principles, 245
  - Smaller Government reforms, 28
  - Smallpox Plan, 179
  - smoking *see* tobacco
  - snow safety, 185, 186, 190
  - Southern, Wendy, 20, 24
  - Specialist Training Program, 169
  - Spencer, Jenean, 277
  - sport and recreation, 6
    - anti-doping measures, 185, 186, 191, 192
    - Girls Make Your Move* campaign, 6, 45, 48, 290
    - integrity measures, 6, 185, 186, 191–192
    - major sporting events, 6, 185, 186, 188–190
    - snow safety, 185, 186, 190
    - sport infrastructure, 187–188
    - strategic priority, 26, 41
    - supporting increased participation, 187
    - water safety, 185, 186, 190
  - Sport and Recreation (Outcome 10)
    - analysis of performance, 184
    - budgeted expenses and resources, 193
    - key community benefits, 185
    - looking ahead, 186
    - performance criteria summary, 185
    - program performance, 186–192
    - programs and objectives, 35, 186
  - Sport and Recreation (Program 10.1)
    - analysis of performance, 186–192
    - budgeted expenses and resources, 193
    - objectives, 186
  - Sporting Schools program, 187
  - Sports Integrity Network, 191
  - Sports Integrity Threat Assessments, 192
  - staff
    - awards, 251
    - Our Behaviours in Action*, 15, 16
    - distribution by location, 262
    - distribution by unit, 260–261
    - employment arrangements, 251–252, 262–263
    - ethical standards, 255
    - feeling valued, 254
    - gender profile, 258
    - Indigenous staff, 256, 260
    - non-salary benefits, 269–270
    - numbers and classifications, 257, 258–259
    - People Strategy 2016–20, 16, 246–247, 256
    - performance management, 247
    - performance pay, 252, 271
    - productivity gains, 255
    - recruitment, 249
    - retention and turnover, 257
    - salary structures, 263–268
    - trainees, 246
    - training, 246, 252–253, 280
    - visibility of senior leaders, 254
    - women in SES, 256
    - work health and safety, 272–275
    - workforce inclusivity, 248–251
    - work-life balance, 255
    - see also* people management; Senior Executive Service staff
  - Staff Survey, 253–255
  - Staff with Disability Network, 276, 277, 279
  - Stakeholder Engagement Framework, 7, 15
  - Standard for the Uniform Scheduling of Medicines and Poisons, 149, 155
  - Statement for Australia's Carers, 276, 279–280
  - statutory office holders, 28
  - stem cell transplants, 144–145
  - Stoma Appliance Scheme, 76, 78, 79
  - stoma products, 76, 78
  - strategic capability, 15
  - Strategic Intent 2016–20*, 15
  - Strategic Policy Committee, 227
  - strategic priorities, 26, 41
  - Streamlining Health and Aged Care Workforce Programme Funding*, 171
  - structure chart, 29–31
  - Stuart, Andrew, 25
  - substance misuse, 58–59
  - Supply Nation Indigenous enterprises, 245
  - Supporting Leave for Living Organ Donors Program, 144
  - sustainable energy initiatives, 287–289
- T**
- Tackling Indigenous Smoking program, 113
  - Targeted Assistance – Aids and Appliances (Program 2.4)
    - analysis of performance, 76–79
    - budgeted expenses and resources, 81
    - objectives, 68
  - Targeted Assistance – Medical (Program 3.2)
    - analysis of performance, 87–89
    - budgeted expenses and resources, 99
    - objectives, 84
  - Targeted Assistance – Pharmaceuticals (Program 2.3)
    - analysis of performance, 75–76
    - budgeted expenses and resources, 80
    - objectives, 68
  - Tasmania, elective surgery reforms, 102, 103, 104–105
  - Taylor Nelson Sofres Pty Limited, 206
  - Technical Industry Working Group on Good Manufacturing Practice, 151
  - TGA Reforms: a blueprint for the TGA's future*, 153
  - Therapeutic Goods Act 1989*, 149
  - alleged breaches, 151

- Therapeutic Goods Administration, 148
    - financial reporting, 296
    - international harmonisation, 152
    - Performance Statistic Report, 149
    - reforms, 152–153
    - regulatory activities, 149–151
  - tick-borne disease, 10
  - tobacco
    - evaluation of product packaging, 46, 56
    - legal challenge to plain packaging measures, 56, 240
    - reducing smoking rates, 45, 56, 57, 59, 113
  - Tobacco Plain Packaging Act 2011*, 56, 241
  - trachoma, 113
  - training see health workforce training; staff training
  - Transition Care Program, 208, 211
- U**
- Under Co-payment dataset, 69
  - UNESCO International Convention Against Doping in Sport, 191
  - United Nations Convention on Biological Diversity, 160
- V**
- vaccine-preventable diseases, 11
  - vaccines and vaccination see immunisation
  - values and behaviours, 27
  - vehicle fleet management, 288
  - veterinary chemicals, 157
  - Victorian Home and Community Care, 196
  - vision, about the Department, 26, 41
  - Visiting Optometrists Scheme, 119, 121
  - Voluntary Dental Graduate Year Programme, 171
  - voucher services, hearing, 83, 96
- W**
- wages see *under* staff
  - Walsh, Michael, 428
  - waste management, 287
  - water conservation, 289
  - water safety, 185, 186, 190
  - Water Safety: Reduce Drownings program, 190
  - Westbrook, Johanna, 428
  - whooping cough (pertussis) booster vaccine, 11
  - work health and safety, 272–275
  - Work Health and Safety Act 2011*
    - notices issued, 275
    - responsibilities under, 272
  - Work Health and Safety Management System audit, 273
  - workers' compensation premium, 272, 274
  - Workforce and Quality (Program 11.5)
    - analysis of performance, 211–215
    - budgeted expenses and resources, 220
    - objectives, 196
  - Workforce and Rural Distribution (Program 8.1)
    - analysis of performance, 167–170
    - budgeted expenses and resources, 173
    - objectives, 166
  - Workforce Development and Innovation (Program 8.2)
    - analysis of performance, 171–172
    - budgeted expenses and resources, 173
    - objectives, 166
  - workforce inclusivity, 248–251
  - Working Group on the Harmonisation of Regulatory Oversight in Biotechnology (OECD), 160
  - workplace agreements see employment arrangements
  - World Anti-Doping Agency, 186
  - World Anti-Doping Code, 191
  - World Cup Twenty20, 186
  - World Health Assembly, 7, 139
  - World Health Organization, 12, 178, 180
    - departmental participation in WHO committees, 7, 12, 13, 21, 131, 139
  - World's Biggest Netball Clinic*, 6, 190
  - Wyatt, Ken, 27, 33
- Y**
- Yannopoulos, Matthew, 20, 22
  - yellow fever, 8
  - young people, mental health services, 117, 118–119
  - young women and sport, 6, 45, 48
- Z**
- Zika virus, 7, 8, 9, 12, 174, 180